Eric A F Simões1,2,3, Viktor Chirikov4, Marc Botteman4, Youngmin Kwon4, Andreas Kuznik5. 1. Department of Pediatrics, University of Colorado School of Medicine, Colorado. 2. Department of Epidemiology, Center for Global Health, Colorado School of Public Health, Colorado. 3. Section of Infectious Disease, Children's Hospital Colorado, Aurora, Colorado. 4. Pharmerit International, Bethesda, Maryland. 5. Regeneron, Tarrytown, New York.
Abstract
BACKGROUND: Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, current burden estimates report only the short-term effects of acute infection. METHODS: Infants with RSV infection and ≥24 months of continuous enrollment were retrospectively identified from the Truven MarketScan database (1 January 2004-30 September 2015). Exposed infants (n = 38 473) were propensity score matched to nonexposed controls (n = 76 825) by baseline characteristics and gestational age. Five-year cumulative all-cause, asthma/wheezing, and respiratory event-related hospitalization rates and physician and emergency department healthcare-resource utilization rates were assessed. RESULTS: During follow-up, RSV-infected cohorts had higher average all-cause cumulative hospitalization rates, compared with controls, with values of 79.9 hospitalizations/100 patient-years (95% confidence interval [CI], 41.7-118.2) for 213 early premature infants (P < .001), 18.2 hospitalizations/100 patient-years (95% CI, .8-35.7) for 397 premature infants (P = .04), 34.2 hospitalizations/100 patient-years (95% CI, 29.1-39.2) for 4446 late premature infants (P < .001), and 16.1 hospitalizations/100 patient-years (95% CI, 14.9-17.4) for 33 417 full-term infants (P < .001). Cumulative rates of physician and emergency department visits were also higher for RSV-infected infants. Asthma/wheezing accounted for 10%-18% of total 5-year physician visits. CONCLUSIONS: Infant RSV infection has a significant long-term healthcare-resource utilization impact across gestational ages for at least 5 years after infection, most of it in the first 2 years. Systematically collecting healthcare-resource utilization data will be important for cost-effectiveness evaluations of RSV interventions in planned or ongoing trials.
BACKGROUND:Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, current burden estimates report only the short-term effects of acute infection. METHODS:Infants with RSV infection and ≥24 months of continuous enrollment were retrospectively identified from the Truven MarketScan database (1 January 2004-30 September 2015). Exposed infants (n = 38 473) were propensity score matched to nonexposed controls (n = 76 825) by baseline characteristics and gestational age. Five-year cumulative all-cause, asthma/wheezing, and respiratory event-related hospitalization rates and physician and emergency department healthcare-resource utilization rates were assessed. RESULTS: During follow-up, RSV-infected cohorts had higher average all-cause cumulative hospitalization rates, compared with controls, with values of 79.9 hospitalizations/100 patient-years (95% confidence interval [CI], 41.7-118.2) for 213 early premature infants (P < .001), 18.2 hospitalizations/100 patient-years (95% CI, .8-35.7) for 397 premature infants (P = .04), 34.2 hospitalizations/100 patient-years (95% CI, 29.1-39.2) for 4446 late premature infants (P < .001), and 16.1 hospitalizations/100 patient-years (95% CI, 14.9-17.4) for 33 417 full-term infants (P < .001). Cumulative rates of physician and emergency department visits were also higher for RSV-infectedinfants. Asthma/wheezing accounted for 10%-18% of total 5-year physician visits. CONCLUSIONS:InfantRSV infection has a significant long-term healthcare-resource utilization impact across gestational ages for at least 5 years after infection, most of it in the first 2 years. Systematically collecting healthcare-resource utilization data will be important for cost-effectiveness evaluations of RSV interventions in planned or ongoing trials.
Authors: Susanna Esposito; Bahaa Abu-Raya; Paolo Bonanni; Fabianne Cahn-Sellem; Katie L Flanagan; Federico Martinon Torres; Asuncion Mejias; Simon Nadel; Marco A P Safadi; Arne Simon Journal: Front Immunol Date: 2021-08-11 Impact factor: 7.561
Authors: Ellen Rafferty; Mike Paulden; Sarah A Buchan; Joan L Robinson; Julie A Bettinger; Manoj Kumar; Lawrence W Svenson; Shannon E MacDonald Journal: Pharmacoeconomics Date: 2022-05-13 Impact factor: 4.558
Authors: Tatiana Chirkova; Christian Rosas-Salazar; Tebeb Gebretsadik; Samadhan J Jadhao; James D Chappell; R Stokes Peebles; William D Dupont; Dawn C Newcomb; Sergejs Berdnikovs; Peter J Gergen; Tina V Hartert; Larry J Anderson Journal: Front Immunol Date: 2022-03-17 Impact factor: 7.561
Authors: Diana M Bowser; Katharine R Rowlands; Dhwani Hariharan; Raíssa M Gervasio; Lauren Buckley; Yara Halasa-Rappel; Elizabeth L Glaser; Christopher B Nelson; Donald S Shepard Journal: J Infect Dis Date: 2022-08-15 Impact factor: 7.759
Authors: Bryan O Nyawanda; Nancy A Otieno; Michael O Otieno; Gideon O Emukule; Godfrey Bigogo; Clayton O Onyango; Shirley Lidechi; Jeremiah Nyaundi; Gayle E Langley; Marc-Alain Widdowson; Sandra S Chaves Journal: J Infect Dis Date: 2022-06-15 Impact factor: 7.759
Authors: Louis Bont; Catherine Weil Olivier; Egbert Herting; Susanna Esposito; Jose Antonio Navarro Alonso; Federico Lega; Silke Mader; Ichiro Morioka; Kunling Shen; George A Syrogiannopoulos; Saul N Faust; Elena Bozzola Journal: Front Pediatr Date: 2022-08-09 Impact factor: 3.569
Authors: Andrew R Connelly; Brian M Jeong; Mackenzie E Coden; Jacob Y Cao; Tatiana Chirkova; Christian Rosas-Salazar; Jacqueline-Yvonne Cephus; Larry J Anderson; Dawn C Newcomb; Tina V Hartert; Sergejs Berdnikovs Journal: Viruses Date: 2021-10-13 Impact factor: 5.048